An open-label Phase II study of combination of TSR-042, bevacizumab, and niraparib in patients with platinum-resistant ovarian cancer (OC): Cohort A of the OPAL trial Liu, J., Gunderson, C., Hendrickson, A., Ratner, E., Diver, E., Moroney, J., Arend, R. C., Louie-Gao, M., Wang, S., Luptakova, K., Konecny, G. E. AMER ASSOC CANCER RESEARCH. 2019

View details for DOI 10.1158/1538-7445.AM2019-CT157

View details for Web of Science ID 000488129900139